Memantine plus sertraline effective for major depressive disorder

Memantine + sertraline effective for major depressive disorder

(HealthDay)—The combination of memantine plus sertraline is efficacious for major depressive disorder, according to a study published online Nov. 3 in the Journal of Clinical Pharmacy and Therapeutics.

Meysam Amidfar, Ph.D., from the Tehran University of Medical Sciences in Iran, and colleagues recruited 66 outpatients with a diagnosis of moderate-to-severe major depressive disorder to participate in a . Sixty-two participants completed six weeks of treatment with memantine plus or placebo plus sertraline. The Hamilton Depression Rating Scale (HDRS) was used to evaluate patients at baseline and at weeks two, four, and six.

The researchers observed a significant time × treatment interaction on the HDRS score in repeated-measures analysis (P = 0.007). The memantine group had significantly greater improvement at all three follow-up sessions, and significantly greater response rates at weeks four and six. The memantine group also had significantly more early improvers and more rapid response to treatment. Both groups had a significant reduction in the HDRS score from baseline to the study end point (both P < 0.001). There were no serious adverse events reported.

"A six-week course of treatment with memantine as adjunct to sertraline showed a favorable safety and efficacy profile in patients with ," the authors write. "Nonetheless, larger controlled studies of longer duration are necessary to assess long-term safety, efficacy, and optimal dosing."


Explore further

CBT, sertraline insufficient in diabetes and depression

More information: Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Memantine plus sertraline effective for major depressive disorder (2016, November 7) retrieved 19 September 2019 from https://medicalxpress.com/news/2016-11-memantine-sertraline-effective-major-depressive.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
21 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more